1Lewin S N. Revised FIGO staging system for endometri- al cancer[J]. Clinical obstetrics and gynecology, 2011, 54 (2): 215-218.
2Pene F, Claessens Y E, Muller O, et al. Role of the phos- phatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma[J]. Oncogene, 2002, 21(43): 6587.
3Ma XM, Blenis J. Molecular mechanisms of roTOR-me- diated translational control[J]. Nat Rev Mol cell Biol, 2009, 10(5): 307-318.
4Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer[J]. Current cancer drug targets, 2008, 8(1): 27-36.
5Asnaghi L, Bruno P, Priulla M, et al. mTOR: a protein kinase switching between life and death[J]. Pharmacolog- ical research, 2004, 50(6): 545-549.
6Schalm S S, Fingar D C, Sabatini D M, et al. TOS mo- tif- mediated raptor binding regulates 4E- BP1 multisite phosphorylation and ftmction[J]. Current biology, 2003, 13(10): 797-806.
7Li Y, Corradetti M N, Inoki K, et al. TSC2: filling the GAP in the mTOR signaling pathway[J]. Trends in bio- chemical sciences, 2004, 29(1): 32-38.
8Llobet D, Pallar6s J, Yeramian A, et al. Molecular pa- thology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints[J]. Journal of clinical pathology, 2009, 62(9): 777-785.
9Salvesen HB, Carter S L, Mannelqvist M, et al. Integrat- ed genomic profiling of endometrial carcinoma associ- ates aggressive tumors with indicators of PI3 kinase acti- vation[J]. Proceedings of the National Academy of Sci- ences, 2009, 106(12): 4834-4839.
10Bansal N, Yendluri V, Wenham RM. The molecular bi- ology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies[J]. Cancer control: journal of the Moffitt Cancer Center, 2009, 16(1): 8.
